Gilead Sciences GILD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.02B+53.7% | $2.18B+22.4% | $3.05B+144% | $1.96B+21.4% | $1.32B+132% | ||
| $218M+4.3% | $230M+3.6% | $230M+6.5% | $225M+7.1% | $209M+11.8% | ||
| $179M+190% | —— | $659M+214% | -$178M-7.2% | -$199M+72.5% | ||
| -$134M-69.6% | —— | $333M+306% | $292M+907% | -$79M-220% | ||
| $52M-76.7% | $123M-45.6% | $515M+506% | $175M+150% | $223M+396% | ||
| -$67M+36.2% | -$95M— | —— | -$162M-95.2% | -$105M-246% | ||
| -$702M-188% | —— | $811M+434% | -$166M+4.6% | -$244M-39.4% | ||
| -$29M+94.7% | -$134M— | -$122M— | -$1.3B-11.0% | -$552M-165% | ||
| $2.54B+44.8% | $3.33B+11.8% | $4.11B-4.7% | $827M-37.6% | $1.76B-20.8% | ||
| $117M+12.5% | $205M+39.5% | $147M+4.3% | $107M-17.7% | $104M-1.0% | ||
| $109M-60.1% | $609M+712% | $167M-70.7% | $21M-86.2% | $273M-93.2% | ||
| $525M— | $1.38B— | $270M— | $2B— | $0-100% | ||
| $1.77B+527% | -$1.84B-716% | -$427M+39.9% | -$2.12B-589% | -$415M+81.2% | ||
| $1.04B+3.0% | $994M+2.2% | $1.01B+2.2% | $994M+2.3% | $1.01B+2.0% | ||
| $419M-42.6% | $230M-34.3% | $435M+45.0% | $527M+427% | $730M+82.5% | ||
| $166M-34.1% | $32M-81.5% | $97M-1.0% | $27M+440% | $252M+72.6% | ||
| -$4.24B-23.7% | -$1.26B— | -$1.49B-8.0% | -$1.57B+46.9% | -$3.43B-152% | ||
| -$11M-158% | $5M+109% | $0-100% | $73M+764% | $19M+206% | ||
| $65M+103% | —— | —— | -$2.78B-43.0% | -$2.07B-51.1% | ||
| $596M-0.5% | $597M-0.2% | $596M0.0% | $598M+0.3% | $599M+0.5% | ||
| $93M-4.1% | $90M-5.3% | $90M-4.3% | $93M-5.1% | $97M+3.2% | ||
| -$5M+58.3% | $36M-75.3% | $368M+546% | -$81M-526% | -$12M-132% | ||
| -$183M-101% | -$267M-353% | -$89M-3.5% | -$33M+62.9% | -$91M+23.5% | ||
| $107M-57.7% | $539M— | $170M-66.3% | $61M+60.5% | $253M-93.9% | ||
| $17M-26.1% | -$11M+68.6% | —— | —— | $23M+560% | ||
| $19M+18.8% | $14M-64.1% | $82M+811% | $21M-38.2% | $16M-96.1% | ||
| $36M— | $23M— | $17M— | $15M— | $0-100% | ||
| $2.52B— | $340M— | $219M— | $295M— | $0-100% | ||
| -$179M-1.7% | -$63M-34.0% | -$137M-67.1% | -$64M-77.8% | -$176M-51.7% | ||
| $2.77B+57.0% | $8M+14.3% | $9M-92.0% | $9M-99.5% | $1.76B— | ||
| $2.43B+46.8% | $3.12B+10.4% | $3.96B-5.0% | $720M-39.7% | $1.65B-21.8% | ||
| $2.43B+46.8% | $3.12B+10.4% | $3.96B-5.0% | $720M-39.7% | $1.65B-21.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $576.0M of capital expenditures, Gilead Sciences's free cash flow was $10.2B over the trailing twelve months, up 3.9% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
